Loading people...
Deepak Atri is a Principal at Foresite Capital in the United States, where he evaluates early-stage investment opportunities across the biotechnology and healthcare sectors. Prior to joining the multi-stage investment firm in 2022, he earned his Doctor of Medicine degree from Yale University, serving as a Howard Hughes Medical Institute research fellow. He subsequently completed his clinical training in internal medicine at The Johns Hopkins Hospital and specialized in cardiovascular medicine at Brigham & Women’s Hospital. Atri further advanced his scientific expertise through a postdoctoral fellowship focused on molecular and population genetics, conducted jointly at Brigham & Women’s Hospital and The Broad Institute of MIT & Harvard. As a physician-scientist, his current professional focus centers on leveraging his extensive clinical and research background to identify, fund, and support emerging life sciences, biotechnology, and therapeutics companies.
Deepak Atri is a key member of the investment team at Foresite Capital, where he holds the position of Analyst. Foresite Capital is renowned for its strategic investments in groundbreaking healthcare and life sciences companies, aiming to support the development of transformative medicines, technologies, and services that address significant unmet medical needs. As an Analyst, Deepak is deeply involved in the rigorous due diligence process that underpins Foresite Capital's investment strategy.
His responsibilities typically include comprehensive market research, competitive analysis, financial modeling, and scientific evaluation of potential investment opportunities. Deepak works closely with senior partners and other team members to identify promising startups and established companies within the biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health sectors. His analytical skills are instrumental in assessing the scientific merit, commercial viability, and potential impact of innovative healthcare solutions.
While specific individual investments for an analyst are often part of a broader team effort and not publicly detailed, Deepak's work contributes directly to Foresite Capital's portfolio, which has historically included companies developing novel therapeutics for oncology, rare diseases, neurological disorders, and infectious diseases, as well as advancements in gene therapy, precision medicine, and healthcare IT platforms. His focus aligns with Foresite's mission to back companies that are poised to make a significant difference in patient care and outcomes.
Deepak Atri's career background likely reflects a strong foundation in science, finance, or a combination of both, which is typical for professionals in this specialized investment field. Individuals in such roles often possess academic credentials in life sciences, biomedical engineering, or finance, coupled with prior experience in research, consulting, or investment banking within the healthcare industry. This multidisciplinary expertise allows him to critically evaluate complex scientific data alongside financial projections and market dynamics.
At Foresite Capital, Deepak Atri is part of a collaborative environment that leverages deep scientific understanding and financial acumen to identify and nurture the next generation of healthcare leaders. His dedication to uncovering valuable opportunities helps Foresite Capital maintain its position as a leading investor in the ever-evolving landscape of healthcare innovation.
Deepak Atri is an Analyst at Foresite Capital, a leading investment firm focused on the healthcare and life sciences sectors. He contributes to evaluating potential investments and supporting strategic decisions.
As part of the Foresite Capital team, Deepak Atri is involved in investments across various healthcare and life sciences areas, including biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health companies.
Deepak Atri works at Foresite Capital, an investment firm dedicated to funding innovative companies in the healthcare and life sciences industries.
